Asterias Biotherapeutics Inc. Warrants (expiring September 29, 2017)
AST.WS
AST.WS was delisted on the 26th of September, 2017.
33 hedge funds and large institutions have $449K invested in Asterias Biotherapeutics Inc. Warrants (expiring September 29, 2017) in 2017 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 6 increasing their positions, 4 reducing their positions, and 2 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 4
24% more capital invested
Capital invested by funds: $362K → $449K (+$87K)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
6% less funds holding
Funds holding: 35 → 33 (-2)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VKH
Virtu KCG Holdings
New York
|
+$10.4K |
| 2 |
CL
CSS LLC
Chicago,
Illinois
|
+$9.63K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$1.18K |
| 4 |
AG
Advisor Group
Phoenix,
Arizona
|
+$18 |
| 5 |
Wells Fargo
San Francisco,
California
|
+$9 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$138 |
| 2 |
Creative Planning
Overland Park,
Kansas
|
-$2 |
AST.WS Hedge Fund Activity: Q2 2017 in Review
33 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Asterias Biotherapeutics Inc. Warrants (expiring September 29, 2017) (AST.WS) for Q2 2017, worth a combined $449K — up 24% from $362K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of AST.WS and 1 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 6 added.
The largest buyer was Virtu KCG Holdings, opening a new position worth an estimated $10.4K. The largest seller was Morgan Stanley, cutting an estimated $138.
- 33 institutional investors held Asterias Biotherapeutics Inc. Warrants (expiring September 29, 2017) (AST.WS) as of Q2 2017, down from 35 in Q1 2017.
- Funds reported $449K of Asterias Biotherapeutics Inc. Warrants (expiring September 29, 2017) stock for Q2 2017, up 24% quarter-over-quarter.
- 1 fund opened new Asterias Biotherapeutics Inc. Warrants (expiring September 29, 2017) positions in Q2 2017 and 2 closed out, a net change of -1 holder.
- The largest Asterias Biotherapeutics Inc. Warrants (expiring September 29, 2017) buyer in Q2 2017 was Virtu KCG Holdings, an estimated $10.4K added.
- The largest Asterias Biotherapeutics Inc. Warrants (expiring September 29, 2017) seller in Q2 2017 was Morgan Stanley, an estimated $138 sold.
Based on aggregated 13F filings for Q2 2017.